(Hypertension. 2000;35:544.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Long-Term Effects of Weight Loss and Dietary Sodium Reduction on Incidence of Hypertension
From the Department of Epidemiology (J.H., P.K.W.), the Tulane University School of Public Health and Tropical Medicine, New Orleans, La; and the Welch Center for Prevention, Epidemiology, and Clinical Research (M.J.K., L.J.A.), Department of Medicine (M.J.K., L.J.A.) and Department of Epidemiology (M.J.K., L.J.A., J.C.), the Johns Hopkins Medical Institutions, Baltimore, Md.
Correspondence to Jiang He, MD, PhD, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 1430 Tulane Ave SL18, New Orleans, LA 70112-2699. E-mail jhe{at}mailhost.tcs.tulane.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—To examine the long-term effects of weight loss and dietary sodium reduction on the incidence of hypertension, we studied 181 men and women who participated in the Trials of Hypertension Prevention, phase 1, in Baltimore, Md. At baseline (1987 to 1988), subjects were 30 to 54 years old and had a diastolic blood pressure (BP) of 80 to 89 mm Hg and systolic BP <160 mm Hg. They were randomly assigned to one of two 18-month lifestyle modification interventions aimed at either weight loss or dietary sodium reduction or to a usual care control group. At the posttrial follow-up (1994 to 1995), BP was measured by blinded observers who used a random-zero sphygmomanometer. Incident hypertension was defined as systolic BP
160
mm Hg and/or diastolic BP 90 mm Hg and/or
treatment with antihypertensive medication during follow-up. Body
weight and urinary sodium were not significantly different among the
groups at the posttrial follow-up. After 7 years of follow-up, the
incidence of hypertension was 18.9% in the weight loss group and
40.5% in its control group and 22.4% in the sodium reduction group
and 32.9% in its control group. In logistic regression
analysis adjusted for baseline age, gender, race, physical
activity, alcohol consumption, education, body weight, systolic
BP, and urinary sodium excretion, the odds of hypertension was reduced
by 77% (odds ratio 0.23; 95% confidence interval 0.07 to 0.76;
P=0.02) in the weight loss group and by 35% (odds ratio
0.65; 95% confidence interval 0.25 to 1.69; P=0.37) in
the sodium reduction group compared with their control groups. These
results indicate that lifestyle modification such as weight loss may be
effective in long-term primary prevention of hypertension.
Key Words: diet, sodium-restricted • blood pressure • hypertension, incidence • weight loss
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Hypertension is an important worldwide public health challenge because of its high prevalence and the concomitant increase in risk of cardiovascular and renal disease. For example,
50 million
adult residents in the United States have hypertension, defined as
having a systolic blood pressure (SBP) 140 mm Hg and/or
diastolic blood pressure (DBP) 90 mm Hg and/or
taking antihypertensive medications.1 Prospective studies
have demonstrated a positive, continuous, and independent association
between higher levels of BP and the risk of coronary heart
disease, stroke, congestive heart failure, end-stage renal disease, and
peripheral vascular disease.2 3 4 5 The benefits
of lowering BP in reducing the risk of coronary heart disease
and stroke have been documented in anti–hypertensive drug treatment
trials.6 7 8 However, treatment of hypertension
represents only a partial response to the overall burden of
BP-related cardiovascular disease in the general
population. To accomplish the broad goal of eliminating all BP-related
diseases in the community, detection and treatment of hypertension must
be complemented by strategies to prevent
hypertension.9 Evidence from observational epidemiological studies has indicated that overweight and high salt intake are important risk factors for hypertension.10 11 12 Clinical trials also have indicated that weight loss and sodium reduction lower BP in hypertensive patients as well as in normotensive patients.13 14 15 16 However, the long-term effects of these interventions on the risk of hypertension are less well established.
The purpose of the present study was to examine the effects of an 18-month lifestyle modification intervention aimed at either weight loss or dietary sodium reduction on the incidence of hypertension during 6 to 8 years of follow-up in a cohort of 181 men and women with high normal BP.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Participants
The Trials of Hypertension Prevention, phase 1 (TOHP-1), was a national, multicenter, randomized controlled trial designed to test the short-term feasibility and efficacy of 3 lifestyle (weight loss, sodium reduction, and stress management) and 4 nutrition supplement (calcium, magnesium, fish oil, and potassium) interventions aimed at lowering blood pressure in those whose DBP was initially in the high normal range (80 to 89 mm Hg).13 14 At the Johns Hopkins clinical center, 289 study participants were randomized into the trial: 60 to the weight loss intervention, 66 to the sodium reduction intervention, 82 to corresponding control groups for weight loss and/or sodium reduction, and 81 to the nutrition supplement intervention and control groups. Participants in the lifestyle modification usual care control group could serve as a control for both the weight loss, if overweight, and/or sodium reduction intervention groups.13 Thus 49 of the 82 participants served as control subjects for the weight loss intervention and all 82 served as control subjects for the sodium reduction group. The principal eligibility criteria for participation in TOHP-1 included age between 30 and 54 years and an average DBP between 80 to 89 mm Hg and SBP <160 mm Hg. The principal exclusion criteria were evidence of hypertension or other cardiovascular disease, extreme obesity (body mass index [BMI]
36.1 kg/m2) or heavy alcohol use
(21 drinks/wk).13 14 Those eligible for inclusion were
further classified into high-weight (BMI of 26.1 to 36.1 for men and
24.3 to 36.1 for women) and low-weight strata (BMI <26.1 for men and
<24.3 for women) before randomization.
Trial Conduct
The weight loss and sodium reduction interventions were
delivered by nutritionists or other experienced counselors and
consisted primarily of group educational sessions, supplemented by
individual counseling.13 14 The group sessions were
attended by 11 to 12 participants and lasted for 90 minutes on each
occasion. They were conducted on a weekly schedule for the first 14 and
10 weeks in weight loss and sodium reduction intervention groups,
respectively. Subsequently, the meetings were held on a semimonthly and
later a monthly frequency throughout the 18-month period of
intervention. The weight loss and sodium reduction interventions
focused on shopping, cooking, and food selection behaviors aimed at
reducing the intake of calories and sodium, respectively. The weight
loss intervention also encompassed a strategy to achieve a moderate
increase in caloric expenditure, primarily by walking at a brisk pace
for 45 minutes, 4 to 5 times per week.
Baseline and follow-up data at 3, 6, 12, and 18 months were collected by specially trained, experienced observers who were blinded to the participants’ treatment assignment, using standardized methods and a stringent level of quality control. All data collectors passed an initial series of certification examinations as well as periodic recertification evaluations. BP measurements were obtained with the use of the Hawksley random-zero modification of the standard mercury sphygmomanometer. BP was measured after the individual had been seated quietly for 5 minutes. The subject was instructed not to eat or smoke for at least 30 minutes before their BP measurements. The first and fifth Korotkoff sounds were recorded as SBP and DBP, respectively. Three BP measurements were recorded at each of 3 visits at the baseline and 12- and 18-month evaluations. Body weight and height were measured with the use of standard protocols. Two 24-hour urine specimens were collected at the baseline and 18-month follow-up visits for estimation of sodium and creatinine excretion.13 14
Posttrial Follow-Up
At the Johns Hopkins clinical center, a posttrial follow-up
examination was conducted between November 1994 and September 1995.
Medical history, especially personal history of hypertension and use of
antihypertensive medication, was evaluated by questionnaire. Three BP
measurements were obtained by trained observers who were blinded to
treatment assignment and who used the same method as for the baseline
visits. Body weight and height were also measured at the posttrial
follow-up visit. A single 24-hour urinary specimen was collected to
assess sodium and creatinine excretion.
Hypertension at follow-up was defined as (1) diagnosis of hypertension
by a physician during the follow-up period and initiation of
antihypertensive therapy as assessed by questionnaire and/or (2) SBP
160 mm Hg and/or (3) DBP 90 mm Hg at the posttrial
follow-up examination. These BP cutpoints have been used for the
definition of hypertension in all TOHP-1 publications because a
BP<160/90 mm Hg was used as an eligibility criterion in TOHP-1.
However, similar results were obtained with the use of a BP
160/95 mm Hg as the definition of hypertension.
Statistical Analysis
Baseline characteristics were compared between the intervention
and control groups for each intervention with the use of Student’s
t tests for continuous variables and
2 tests for categorical variables. Changes
from baseline in weight, 24-hour urinary excretion of sodium, and SBP
and DBP were compared between intervention and control groups with the
use of Student’s t tests. The incidence of hypertension was
compared between intervention and control groups with the use of
2 tests. Logistic regression analysis
was used to compare the risk of hypertension between the intervention
and control groups after adjustment for important risk factors for
hypertension, including age, gender, baseline physical activity,
alcohol consumption, education, weight, SBP, and urinary excretion of
sodium. Two-tailed probability values are reported. All
analyses were performed with the use of SAS
software.17
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Of the 208 trial participants who were randomized into the weight loss, sodium reduction, or control groups, 181 (87.0%) took part in the posttrial follow-up examination conducted, on average, 7 years later. Among the 27 nonrespondents, 1 had died, 1 was seriously ill, and the remaining 25 refused to participate. The baseline mean age, body weight, SBP, and DBP as well as the percentage who were men, white, college graduates, current smokers, and alcohol drinkers (
1
drink/wk) was similar in the 27 nonrespondents compared with the 181
respondents. However, baseline 24-hour urinary excretion of sodium was
significantly lower in the nonrespondents (127 mmol/L) compared
with the respondents (153 mmol/L) (P=0.01). There were
no significant differences in any of the previously mentioned baseline
characteristics, including 24-hour urinary excretion of sodium, between
the respondents and nonrespondents across randomization groups.
Baseline Characteristics
Baseline characteristics of the 181 study participants are
presented in Table 1. The
average age of study participants was 43 years at baseline. Fifty-seven
percent were men; 58% were white; and 46% were college graduates. The
mean BP at baseline was 122 mm Hg for SBP and 84 mm Hg for
DBP. Mean body weight was 81 kg, and urinary excretion of sodium was
153 mmol/24 h. Eighteen percent of the participants were current
cigarette smokers and 39% of them were alcohol drinkers (1
drink/wk). Sixty-two percent of the participants engaged in vigorous
exercise leading to perspiration 1 time per week. For both weight
loss and sodium reduction, there were no significant differences in the
baseline characteristics of the intervention and control groups (all
P>0.05).
|
18-Month Intervention Results
During the 18 months of active intervention, body weight decreased
by 2.4 kg in the weight loss intervention group; the net difference in
weight loss between the weight loss intervention and control groups was
3.5 kg (P<0.001) (Table 2).
The corresponding reduction in SBP was 6.9 mm Hg in the
intervention group and 1.2 mm Hg in the control group, yielding a
net reduction in SBP associated with weight loss of 5.8 mm Hg
(P<0.001). The decline in DBP was 8.6 mm Hg in the
weight loss group and 5.5 mm Hg in control group, yielding a net
reduction in DBP associated with weight loss of 3.2 mm Hg
(P=0.005).
|
Over the 18-month period in which the trial was conducted, excretion of urinary sodium declined by 53.5 mmol/24 h in the sodium reduction intervention group and 20.2 mmol/24 h in their control group (Table 2), yielding a net reduction in urinary sodium excretion of 33.3 mmol/24 h between the active intervention and control groups. The corresponding reduction in SBP was 5.7 mm Hg in the sodium reduction group and 2.4 mm Hg in the control group, yielding a net reduction in SBP associated with sodium reduction of 3.3 mm Hg (P=0.01). The decline in DBP was 7.2 mm Hg in the sodium reduction intervention group and 5.6 mm Hg in the control group, yielding a net reduction in DBP of 1.7 mm Hg (P=0.08).
The cumulative incidence of hypertension over the 18 months of
follow-up was 1.67% in the weight loss intervention group and 8.16%
in the weight loss control group (2=2.60,
P=0.11). The corresponding cumulative incidence of
hypertension was 6.06% in the sodium reduction intervention group and
9.76% in the sodium reduction control group
(2=0.67, P=0.41).
Posttrial Follow-Up Results
Over an average of 7 years of follow-up, changes from baseline in
body weight were similar in the weight loss active intervention (4.9
kg) and control groups (4.5 kg) (Table 3). Compared with baseline, SBP increased
by 2.0 and 3.7 mm Hg in the active intervention and control
groups, respectively. The net change in SBP was -1.8 mm Hg in
the weight loss group compared with its control group
(P=0.52). DBP decreased 6.5 mm Hg in the weight loss
active intervention group and 5.2 mm Hg in the weight loss
control group, yielding a net change in DBP of -1.3 mm Hg in the
weight loss group compared with its control group (P=0.42).
The cumulative percentage of anti–hypertensive medication use was
13.2% in the weight loss active intervention group and 28.6% in
weight loss control group (P=0.06). Over the 7 years of
follow-up, changes in urinary excretion of sodium were not
significantly different between the sodium reduction active
intervention group (10.8 mmol/24 h) and control group (0.3
mmol/24 h). The corresponding changes in SBP were -1.6 mm Hg for
the active intervention and +2.2 mm Hg for the control group,
yielding a net change in SBP of -3.8 mm Hg over the 7 years of
follow-up (P=0.08). DBP decreased by 7.5 and 5.3 mm Hg
in the sodium reduction active intervention and control groups,
respectively, yielding a net change of -2.3 mm Hg over the 7
years of follow-up (P=0.097). The cumulative percentage of
antihypertensive medication use was 19.0% and 24.3% in the sodium
reduction active intervention and control groups, respectively
(P=0.47).
|
Over the 7 years of follow-up, the incidence of hypertension was 18.9% and 40.5% in the weight loss active intervention and control groups, respectively (P=0.02) (Figure). The incidence of hypertension was 22.4% and 32.9% in the sodium reduction active intervention and control groups, respectively (P=0.19). In logistic regression analysis, weight loss was associated with a 66% reduction (odds ratio [OR] 0.34; 95% confidence interval[CI] 0.14 to 0.86; P=0.02) in the odds of hypertension (Table 4). After adjustment for age, gender, race, and baseline physical activity, alcohol consumption, education, weight, SBP, and urinary sodium excretion, weight loss was associated with a 77% reduction (OR 0.23; 95% CI 0.07 to 0.76; P=0.02) in the odds of hypertension. In univariate logistic regression analysis, sodium reduction was associated with a 41% reduction (OR 0.59; 95% CI 0.27 to 1.31; P=0.19) in the odds of hypertension; in multivariate logistic regression analysis, sodium reduction was associated with a 35% reduction (OR 0.65; 95% CI 0.25 to 1.69; P=0.37) in the odds of hypertension.
|
|
Body fat distribution was not measured at the baseline examination. However, waist-to-hip ratio was not significantly different between the active intervention and control groups for weight loss (0.92 vs 0.90 cm/cm, P=0.28) or for sodium reduction (0.90 vs 0.89 cm/cm, P=0.81) interventions at the posttrial follow-up examination. Likewise, the percentage of participants who were exercising vigorously at least once per week was not significantly different between the active intervention and control groups for the weight loss (76.9% vs 71.4%, P=0.54) or sodium reduction (75.9% vs 70.0%, P=0.46) interventions at the posttrial follow-up examination.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Several randomized controlled trials have documented the value of weight loss and dietary sodium reduction in decreasing the risk of hypertension.14 15 16 However, our study is the first one to demonstrate the long-term effects of short-term weight loss and sodium reduction on the incidence of hypertension. Over an average follow-up of 7 years, an 18-month weight loss intervention program was significantly associated with a 77% reduction in the incidence of hypertension, and a corresponding sodium reduction program was associated with a 35% reduction in the incidence of hypertension. The latter did not reach the customary level for designation of statistical significance, possibly as a result of the small sample size of the cohort under study.
TOHP-1 was not designed to examine the long-term effects of weight loss and sodium reduction interventions on the risk of hypertension. Therefore after 18-months, there was no further contact with the trial participants to enhance the intervention effect. After 7 years, the intervention effects on body weight and urinary sodium excretion had all but disappeared, but the beneficial effect on risk of hypertension was still evident. The mechanisms for the apparent long-term benefit of the intervention are uncertain. In a recent study, Geleijnse and colleagues18 compared BP levels in 71 children who were assigned to a low sodium diet during the first 6 months of life with 98 children who were assigned to a usual sodium diet. After 15 years of follow-up, SBP was -3.6 mm Hg lower and DBP was -2.2 mm Hg lower in the children who had been assigned to the low sodium group compared with the control group, although urinary sodium excretion was not significantly different between the 2 groups.
The long-term intervention effect observed in our study was unlikely to have been due to an error in measurement of the outcomes of interest. BP was measured by trained observers who were blinded to the intervention assignment of our study participants. The follow-up procedures and schedules as well as the criteria for diagnosis of hypertension were identical for the participants who were allocated to the intervention or control groups. The long-term effect also was unlikely to have been due to other potentially confounding baseline variables because our comparisons were based on the participant’s randomization assignments. However, we cannot rule out the possibility of a confounding effect caused by change in body weight or sodium intake in the usual care control group after the diagnosis of hypertension. This confounding effect would be expected to result in a diminution of the observed differences in body weight, urinary excretion of sodium, BP, and incidence of hypertension between the intervention and control groups.
The role of overweight in the cause of hypertension has been explored in many large epidemiological studies, and the effect of weight loss in the prevention and treatment of hypertension has been tested in a smaller number of clinical trials.19 Both cross-sectional and longitudinal studies have consistently identified an association between overweight and hypertension independent of other risk factors for hypertension.19 Several clinical trials also have shown a BP-lowering effect of weight loss.14 16 17 20 In the Hypertension Prevention Trial, a 4% reduction in body weight over 3 years was associated with a -2.4 mm Hg lower in SBP and -1.8 mm Hg lower in DBP.16 In TOHP-1, assignment to the weight loss intervention was associated with an average weight loss of 3.9 kg, a SBP reduction of 2.9 mm Hg, and a DBP reduction of 2.3 mm Hg (all P<0.01) over an 18-month period of follow-up in a group of 35- to 54-year-old men and women with high normal DBP.14 The weight loss intervention also produced a 51% (95% CI 29% to 83%) reduction in the incidence of hypertension.14 Weight loss intervention was associated with a 21% reduction (P=0.02) in the incidence of hypertension over a 36-month period of follow-up in the Trials of Hypertension Prevention, phase II.17 These data and our observations indicate that weight loss is an important approach for primary prevention of hypertension.
Results from both observational epidemiological studies and randomized controlled trials have identified a dose-response association between dietary sodium intake and BP in human populations.21 During the past 30 years, >60 randomized controlled trials have been conducted in hypertensive or normotensive participants. Recently, several meta-analyses were conducted to pool the results from these trials.22 23 Midgley et al22 identified 28 trials conducted in normotensive participants (n=2374) who met their inclusion criteria. For the trials conducted in normotensive participants, the mean reduction in daily urinary sodium excretion, a proxy measure of dietary sodium intake, was 125 mmol (95% CI 95 to 156 mmol). Compared with the control group, the net change was -1.6 mm Hg (95% CI -2.4 to -0.9 mm Hg) for SBP and -0.5 mm Hg (-1.2 to 0.1 mm Hg) for DBP. In another meta-analysis by Cutler et al,23 the pooled estimates of BP reduction for 12 trials conducted in normotensive persons (n=1689) were -1.9 mm Hg (95% CI -1.2 to -2.6) for SBP and -1.1 mm Hg (-0.6 to -1.6) for DBP.23 A major limitation of these meta-analyses is the fact that most of the trials that were included were of short duration. For example, the median duration of follow-up for the normotensive trials in the meta-analysis by Midgley et al was 14 days. In TOHP-1, the sodium reduction intervention lowered the average urinary sodium excretion by 44 mmol/24 h (P<0.01), DBP by 0.9 mm Hg (P<0.05), and SBP by 1.7 mm Hg (P<0.01) over an 18-month period of follow-up in persons with high normal BP.14 The sodium reduction intervention was also associated with a lower incidence of hypertension over the 18-month period of follow-up (relative risk 0.84; 95% CI 0.62, 1.13), but this reduction was not statistically significant.14 Our study, with a follow-up period of 7 years, suggests that the short-term reduction in sodium intake may be associated with a lower long-term risk of hypertension. However, our results also did not reach a customary level of statistical significance because of the small sample size available for the analysis.
Our findings have important public health implications. Hypertension is a common and important modifiable risk factor for cardiovascular disease and total deaths. Lifestyle modifications such as weight loss and sodium reduction should be recommended as a principal component of strategies to prevent hypertension and its complications in the US general population.
|
Acknowledgments |
|---|
This study was supported by grant HL-37924 from the National Heart, Lung, and Blood Institute, National Institutes of Health, an American Heart Association Maryland Affiliate grand-in-aid (MDBG1195), and partially by Outpatient General Research Center grant 5-M01-RR-00722 from the National Institutes of Health. Dr He was supported by training grant 5-T32-HL-07024 from the National Heart, Lung, and Blood Institute, National Institutes of Health. The authors would like to thank the study coordinators, Dolores Kaidy and Deborah Schafauser; and research technicians, Sharon Capelli, Shirley George, Charles Harris, Vicki Harris, Estelle Levitas, Selma Schlenhoff, and Bobbie Weiss, at the Johns Hopkins Pro-Health Research Office for their excellent technical assistant during this project.
Received May 20, 1999; first decision June 21, 1999; accepted September 24, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25:305–313.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease, I: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–774.[Medline] [Order article via Infotrieve]
3. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951–957.[Medline] [Order article via Infotrieve]
4.
Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati
FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal
disease in men. N Engl J Med. 1996;334:13–18.
5. Whelton PK, He J, Klag MJ. Blood pressure in Westernized populations. In: Swales JD, ed. Textbook of Hypertension. Oxford, UK: Blackwell Scientific Publications: 1994:11–21.
6. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838.[Medline] [Order article via Infotrieve]
7.
Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH.
Recent evidence on drug therapy of mild to moderate hypertension and
decreased risk of coronary heart disease. Arch Intern
Med. 1993;153:578–581.
8. Whelton PK, He J. Prevention trials of blood pressure reduction. In: Hennekens C, Buring J, Furberg C, Manson JE, eds. Clinical Trials in Cardiovascular Disease. Philadelphia, Pa: WB Saunders; 1999.
9.
Working Group on Primary Prevention of Hypertension.
National High Blood Pressure Education Program Working Group Report on
Primary Prevention of Hypertension. Arch Intern Med. 1993;153:186–208.
10. Staessen J, Fagard R, Lijnen P, Amery A. Body weight, sodium intake and blood pressure. J Hypertens. 1989;7:S19–23.
11. He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am. 1997;81:1077–1097.[Medline] [Order article via Infotrieve]
12. He J, Whelton PK. What is the role of dietary sodium and potassium in hypertension and target organ injury? Am J Med Sci. 1999;317:152–159.[Medline] [Order article via Infotrieve]
13. Satterfield S, Cutler JA, Langford HG, Applegate WB, Borhani NO, Brittain E, Cohen JD, Kuller LH, Lasser NL, Oberman A, Rosner B, Taylor JO, Vogt TM, Walker WG, Whelton PK. Trials of hypertension prevention, phase 1 design. Ann Epidemiol. 1991;1:455–471.[Medline] [Order article via Infotrieve]
14. Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention Phase 1. JAMA 267;1992:1213–1220.
15.
Hypertension Prevention Trial Research Group. The
Hypertension Prevention Trial (HPT): 3-year effects of dietary changes
in blood pressure. Arch Intern Med. 1990;150:153–162.
16.
Trials of Hypertension Prevention Collaborative
Research Group. Effects of weight loss and sodium reduction
intervention on blood pressure and hypertension incidence in overweight
people with high-normal blood pressure: the Trials of Hypertension
Prevention, Phase II. Arch Intern Med. 1997;157:657–667.
17. SAS Institute Inc. SAS/STAT User’s guide, version 7-1. Cary, NC: SAS Institute Inc; 1998.
18.
Geleijnse JM, Hofman A, Witteman JCM, Hazebroek AAJM,
Valkenburg HA, Grobbee DE. Long-term effects of neonatal sodium
restriction on blood pressure. Hypertension. 1997;29:913–917.
19. MacMahon S, Cutler J, Brittain E, Higgins M. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J. 1987;8(suppl B):57–70.
20.
Schotte DE, Stunkard AJ. The effects of weight
reduction on blood pressure in 302 obese patients. Arch Intern
Med. 1990;150:1701–1704.
21. He J, Whelton PK. Role of sodium reduction in the treatment and prevention of hypertension. Curr Opin Cardiol. 1997;12:202–207.[Medline] [Order article via Infotrieve]
22.
Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect
of reduced dietary sodium on blood pressure: a meta-analysis of
randomized controlled trials. JAMA. 1996;275:1590–1597.
23.
Cutler JA, Follmann D, Allender PS. Randomized trials
of sodium reduction: an overview. Am J Clin Nutr. 1997;65:643S–651S.
This article has been cited by other articles:
 |
|
 |
|
  M. Kivimaki, G. D. Batty, A. Singh-Manoux, J. E. Ferrie, A. G. Tabak, M. Jokela, M. G. Marmot, G. D. Smith, and M. J. Shipley Validating the Framingham Hypertension Risk Score: Results From the Whitehall II Study Hypertension, September 1, 2009; 54(3): 496 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Chobanian The Hypertension Paradox -- More Uncontrolled Disease despite Improved Therapy N. Engl. J. Med., August 27, 2009; 361(9): 878 - 887. [Full Text] [PDF]
|
|
|
|
 |
|
 I. J Brown, I. Tzoulaki, V. Candeias, and P. Elliott Salt intakes around the world: implications for public health Int. J. Epidemiol., June 1, 2009; 38(3): 791 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Harsha and G. A. Bray Weight Loss and Blood Pressure Control (Pro) Hypertension, June 1, 2008; 51(6): 1420 - 1425. [Full Text] [PDF]
|
|
|
|
 |
|
 N. I. Parikh, M. J. Pencina, T. J. Wang, E. J. Benjamin, K. J. Lanier, D. Levy, R. B. D'Agostino Sr, W. B. Kannel, and R. S. Vasan A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study Ann Intern Med, January 15, 2008; 148(2): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. O'Neil and T. A. Nicklas State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health American Journal of Lifestyle Medicine, December 1, 2007; 1(6): 457 - 481. [Abstract] [PDF]
|
|
|
|
 |
|
 P. R. Conlin Eat Your Fruits and Vegetables But Hold the Salt Circulation, October 2, 2007; 116(14): 1530 - 1531. [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Welty, K. S. Lee, N. S. Lew, and J.-R. Zhou Effect of Soy Nuts on Blood Pressure and Lipid Levels in Hypertensive, Prehypertensive, and Normotensive Postmenopausal Women Arch Intern Med, May 28, 2007; 167(10): 1060 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R Cook, J. A Cutler, E. Obarzanek, J. E Buring, K. M Rexrode, S. K Kumanyika, L. J Appel, and P. K Whelton Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP) BMJ, April 28, 2007; 334(7599): 885 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Samal, S. Greisenegger, E. Auff, W. Lang, and W. Lalouschek The Relation Between Knowledge About Hypertension and Education in Hospitalized Patients With Stroke in Vienna Stroke, April 1, 2007; 38(4): 1304 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Zillich and S. T. Haines ASHP Therapeutic Position Statement on the Treatment of Hypertension. Am. J. Health Syst. Pharm., June 1, 2006; 63(11): 1074 - 1080. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chockalingam, N. Ganesan, S. Venkatesan, G. Gnanavelu, T. Subramaniam, V. Jaganathan, S. Elangovan, R. Alagesan, S. Dorairajan, A. Subramaniam, et al. Patterns and Predictors of Prehypertension Among "Healthy" Urban Adults in India Angiology, September 1, 2005; 56(5): 557 - 563. [Abstract] [PDF]
|
|
|
|
 |
|
 The American Diabetes Association, the North American Association for the Study of Ob, and and the American Society for Clinical Nutrition Weight Management Using Lifestyle Modification in the Prevention and Management of Type 2 Diabetes: Rationale and Strategies Clin. Diabetes, July 1, 2005; 23(3): 130 - 136. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Boustany, D. R. Brown, D. C. Randall, and L. A Cassis AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2005; 289(1): R181 - R186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Svetkey Management of Prehypertension Hypertension, June 1, 2005; 45(6): 1056 - 1061. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Klein, N. F Sheard, X. Pi-Sunyer, A. Daly, J. Wylie-Rosett, K. Kulkarni, and N. G Clark Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Am. J. Clinical Nutrition, August 1, 2004; 80(2): 257 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Klein, N. F. Sheard, X. Pi-Sunyer, A. Daly, J. Wylie-Rosett, K. Kulkarni, and N. G. Clark Weight Management Through Lifestyle Modification for the Prevention and Management of Type 2 Diabetes: Rationale and Strategies: A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Diabetes Care, August 1, 2004; 27(8): 2067 - 2073. [Full Text] [PDF]
|
|
|
|
 |
|
 National High Blood Pressure Education Program Wor The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents Pediatrics, August 1, 2004; 114(2/S2): 555 - 576. [Full Text] [PDF]
|
|
|
|
|
|
V. Franco, S. Oparil, and O. A. Carretero Hypertensive Therapy: Part II Circulation, June 29, 2004; 109(25): 3081 - 3088. [Full Text] [PDF]
|
|
|
|
|
|
V. Franco, S. Oparil, and O. A. Carretero Hypertensive Therapy: Part I Circulation, June 22, 2004; 109(24): 2953 - 2958. [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. HERMAN, J. L. KONZELMAN JR., and L. M. PRISANT New national guidelines on hypertension: A summary for dentistry J Am Dent Assoc, May 1, 2004; 135(5): 576 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Williams, N. R Poulter, M. J Brown, M. Davis, G. T McInnes, J. F Potter, P. S Sever, and S. M. Thom British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary BMJ, March 13, 2004; 328(7440): 634 - 640. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kivimaki, M.-L. Kinnunen, T. Pitkanen, J. Vahtera, M. Elovainio, and L. Pulkkinen Contribution of Early and Adult Factors to Socioeconomic Variation in Blood Pressure: Thirty-Four-Year Follow-up Study of School Children Psychosom Med, March 1, 2004; 66(2): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. DeCrane Have We Underestimated the Effects of Sodium Excess on the Health of the Public? Policy Politics Nursing Practice, February 1, 2004; 5(1): 25 - 33. [Abstract] [PDF]
|
|
|
|
|
|
R. B. de Paula, A. A. da Silva, and J. E. Hall Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration Hypertension, January 1, 2004; 43(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension, December 1, 2003; 42(6): 1206 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Neter, B. E. Stam, F. J. Kok, D. E. Grobbee, and J. M. Geleijnse Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials Hypertension, November 1, 2003; 42(5): 878 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report JAMA, May 21, 2003; 289(19): 2560 - 2571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Logan Lifestyle Modifications to Prevent Hypertension JAMA, February 19, 2003; 289(7): 843 - 843. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Whelton, J. He, and L. J. Appel Lifestyle Modifications to Prevent Hypertension JAMA, February 19, 2003; 289(7): 843 - 844. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Whelton, J. He, L. J. Appel, J. A. Cutler, S. Havas, T. A. Kotchen, E. J. Roccella, R. Stout, C. Vallbona, M. C. Winston, et al. Primary Prevention of Hypertension: Clinical and Public Health Advisory From the National High Blood Pressure Education Program JAMA, October 16, 2002; 288(15): 1882 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hooper, C. Bartlett, G. Davey Smith, and S. Ebrahim Systematic review of long term effects of advice to reduce dietary salt in adults BMJ, September 21, 2002; 325(7365): 628 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Warner Complementary and Alternative Therapies for Hypertension Complementary Health Practice Review, October 1, 2000; 6(1): 11 - 19. [PDF]
|
|
|
|
 |
|
 Preventing Long-Term Hypertension Journal Watch Cardiology, March 31, 2000; 2000(331): 9 - 9. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||